Oxea Announces Price Increases for Amines
OBERHAUSEN, Germany--(BUSINESS WIRE)-- Oxea will increase list and off-list prices on the following products effective immediately, or as contracts allow. The price increase is driven by continued cost increases for raw materials in Europe.
| Europe | Asia |
Middle East,Africa |
||||||||||
| Product | EUR/mt | USD/mt | USD/mt | |||||||||
| n-Butylamine | + 80 | + 90 | + 90 | |||||||||
| Di-n-butylamine | + 80 | + 90 | + 90 | |||||||||
| Tri-n-butylamine | + 80 | + 90 | + 90 | |||||||||
| 2-Ethylhexylamine | + 80 | + 90 | + 90 | |||||||||
| Di-2-ethylhexylamine | + 80 | + 90 | + 90 | |||||||||
About Oxea
Oxea is a global manufacturer of oxo intermediates and oxo derivatives, such as alcohols, polyols, carboxylic acids, specialty esters, and amines. These products are used for the production of high-quality coatings, lubricants, cosmetics and pharmaceutical products, flavorings and fragrances, printing inks and plastics. Oxea employs more than 1,400 people worldwide. Oxea is owned by Oman Oil Company S.A.O.C. For more information about Oxea, visit www.oxea-chemicals.com
About Oman Oil Company
Oman Oil Company S.A.O.C. (OOC) is a commercial company wholly owned by the Government of Oman. It was established in 1996 to pursue investment opportunities in the wider energy sector both inside and outside Oman. The Company plays an important role in the Sultanate's efforts to diversify the economy and to promote domestic and foreign investments.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528006725/en/
OXEA GmbH
Dr. Christoph Balzarek, Commercial Business Director
Amines, Higher Aldehydes & Specialty Derivatives
Phone: +49
(0)208 693 3181
fax: +49 (0)208 693-2050
[email protected]
www.oxea-chemicals.com
Source: Oxea
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MEDDDICAL Launches German Claims Data Access Advisory for Pharma & MedTech
- Beyond Mums: Proven Winners® Inspires With Showstopping Fall Porch Combinations
- Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Raising PricesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share